Evidence map›Paper›PMID 39384827›Full record

ArticleScientific reports2024

Distinct copy number signatures between residual benign and transformed areas of carcinoma ex pleomorphic adenoma.

João Figueira Scarini, Wellington Lima Sabino, Reydson Alcides de Lima-Souza, Erika Said Abu Egal, Alfio José Tincani, Rogério Gondak, Luiz Paulo Kowalski, Ana Cristina Victorino Krepischi, Albina Altemani, Fernanda Viviane Mariano

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

João Figueira Scarini *Department of Pathology, Faculty of Medical Sciences (FCM), University of Campinas (UNICAMP), 126, Tessalia Vieira de Camargo Street, Cidade Universitaria, Campinas, São Paulo, 13083887, Brazil. scarinij@gmail.com.
Wellington Lima Sabino *Department of Pathology, Faculty of Medical Sciences (FCM), University of Campinas (UNICAMP), 126, Tessalia Vieira de Camargo Street, Cidade Universitaria, Campinas, São Paulo, 13083887, Brazil.
Reydson Alcides de Lima-SouzaDepartment of Pathology, Faculty of Medical Sciences (FCM), University of Campinas (UNICAMP), 126, Tessalia Vieira de Camargo Street, Cidade Universitaria, Campinas, São Paulo, 13083887, Brazil.
Erika Said Abu EgalDepartment of Pathology, Faculty of Medical Sciences (FCM), University of Campinas (UNICAMP), 126, Tessalia Vieira de Camargo Street, Cidade Universitaria, Campinas, São Paulo, 13083887, Brazil.
Alfio José TincaniDepartment of Head and Neck Surgery, Faculty of Medical Sciences (FCM), University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
Rogério GondakDepartment of Pathology, Federal University of Santa Catarina (UFSC), Florianópolis, Santa Catarina, Brazil.
Luiz Paulo KowalskiDepartment of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer Center, São Paulo, São Paulo, Brazil.
Ana Cristina Victorino KrepischiDepartment of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo (USP), São Paulo, São Paulo, Brazil.
Albina AltemaniDepartment of Pathology, Faculty of Medical Sciences (FCM), University of Campinas (UNICAMP), 126, Tessalia Vieira de Camargo Street, Cidade Universitaria, Campinas, São Paulo, 13083887, Brazil.
Fernanda Viviane MarianoDepartment of Pathology, Faculty of Medical Sciences (FCM), University of Campinas (UNICAMP), 126, Tessalia Vieira de Camargo Street, Cidade Universitaria, Campinas, São Paulo, 13083887, Brazil. fmariano@unicamp.br.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 153411/2017-1Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado de São Paulo 15/07304-0; 17/13167-1; 17/00831-0; 2019/09419-0
6 · The paper itself

Abstract

The mechanisms involved with the pathogenesis of carcinoma ex pleomorphic adenoma (CXPA) seem to be associated with the accumulation of molecular alterations in the pleomorphic adenoma (PA). In this sense, using array-based comparative genomic hybridization (aCGH) a rare series of 27 cases of CXPA and 14 residual PA (rPA) adjacent to the transformation area, we investigated the profile of the copy number alterations (CNAs) comparing benign residual and transformed areas. The main findings were correlated with the histopathological classification by histologic subtype and degree of invasion. The distribution of losses (p = 0.187) and amplifications (p = 0.172) was not statistically different between rPA and CXPA. The number of gains was increased in the transformed areas compared to the benign residual areas (p = 0.005). PLAG1 gain was maintained along the malignant transformation, as it was observed in both residual PA and CXPA samples, likely being an earlier event during transformation. The amplification of GRB7 and ERBB2 may also be an initial step in the malignant transformation of PA to CXPA (salivary duct carcinoma subtype). Furthermore, the amplification of HMGA2 and RPSAP52 were the most prevalent alterations among the studied samples. It was noteworthy that amplified genes in the transformed areas of the tumors were enriched for biological processes related to immune signaling. In conclusion, our results underscored for the first-time crucial CNAs in CXPA, some of them shared with the residual benign area adjacent to the transformation site. These CNAs included PLAG1 gain, as well as amplification of GRB7, ERBB2, HMGA2, and RPSAP52.

Indexed as

Adenoma, PleomorphicComparative Genomic HybridizationDNA Copy Number VariationsAdultAgedCell Transformation, NeoplasticDNA-Binding ProteinsErb-b2 Receptor Tyrosine KinasesFemaleHMGA2 ProteinHumansMaleMiddle AgedSalivary Gland NeoplasmsDNA-Binding ProteinsErb-b2 Receptor Tyrosine KinasesHMGA2 ProteinPLAG1 protein, humanArray-based comparative genomic hybridizationCarcinoma ex pleomorphic adenomaCopy number alterationGenePleomorphic adenoma

Identifiers

PMID39384827
PMCPMC11464513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.